The Feasibility of FLT3 Inhibitors in Combination Therapies: From Safety to Survival in AML

The Feasibility of FLT3 Inhibitors in Combination Therapies: From Safety to Survival in AML

Key Findings from EHA 2024 in AML: Canadian Experts Weigh In
Icon Objectives

Learning Objectives

Upon completion of this program, participants will be able to:

  1. Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
  2. Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
  3. Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
Icon Chair Speaker

Speakers

Dr. Anna Spreafico

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • ADMIRAL trial
  • Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
  • PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Tagged